(Q50922761)

English

The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial.

scientific article published in November 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/17022791

The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/17022791

0 references

1 reference

based on heuristic

inferred from title

chronic schizophrenia

1 reference

based on heuristic

inferred from title

author name string

Y Lecrubier

1

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/17022791

P Quintin

2

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/17022791

M Bouhassira

3

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/17022791

E Perrin

4

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/17022791

S Lancrenon

5

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/17022791

language of work or name

0 references

publication date

1 November 2006

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/17022791

Acta Psychiatrica Scandinavica

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/17022791

114

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/17022791

5

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/17022791

319-327

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/17022791

A separate disease within the syndrome of schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00887.X

21 January 2018

How many and which are the psychopathological dimensions in schizophrenia? Issues influencing their ascertainment.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00887.X

21 January 2018

Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00887.X

21 January 2018

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00887.X

21 January 2018

A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00887.X

21 January 2018

Psychomotor symptoms of depression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00887.X

21 January 2018

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00887.X

21 January 2018

Negative symptoms in schizophrenia: considerations for clinical trials. Working group on negative symptoms in schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00887.X

21 January 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00887.X

21 January 2018

Treatment outcomes in schizophrenia: implications for practice, policy, and research

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00887.X

21 January 2018

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.2006.00887.X

21 January 2018

Identifiers

10.1111/J.1600-0447.2006.00887.X

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/17022791

release_sncwlo3ocrd6nekr2bllcbiude

1 reference

https://api.fatcat.wiki/v0/release/sncwlo3ocrd6nekr2bllcbiude

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

25 March 2018

http://europepmc.org/abstract/MED/17022791

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50922761&oldid=1836892537"